FDA Approves INVOKAMET — Janssen Pharmaceuticals, Inc.

Janssen Pharmaceuticals, Inc. announced the approval of INVOKAMET (canagliflozin and metformin hydrochloride) for oral use on August 8, 2014, creating a high-potential combination therapy that allows patients to simplify their regimen while addressing glycemic control. This launch capitalizes on the increasing dominance of sodium-glucose cotransporter-2 inhibitors, positioning Janssen to directly compete in the expanding antidiabetic market against SGLT2-focused heavyweights.